Ma Y - Search Results

1

Prediction of SHP2-E76K binding sites based on molecular dynamics simulation and Markov algorithm.

Zhang SP, Chen LJ, Shi ZL, Li X, Ma Y. Zhang SP, et al. Among authors: ma y. J Biomol Struct Dyn. 2024 Nov 19:1-12. doi: 10.1080/07391102.2024.2431193. Online ahead of print. J Biomol Struct Dyn. 2024. PMID: 39558779

2

Exploring the mechanism of C473D mutation on CDC25B causing weak binding affinity with CDK2/CyclinA by molecular dynamics study.

Li LP, Li HX, Zhou H, Li WY, Wang RL, Zhang YC, Ma Y. Li LP, et al. Among authors: ma y. J Biomol Struct Dyn. 2023;41(22):12552-12564. doi: 10.1080/07391102.2023.2166995. Epub 2023 Jan 19. J Biomol Struct Dyn. 2023. PMID: 36655391

3

Setmelanotide optimization through fragment-growing, molecular docking in-silico method targeting MC4 receptor.

Jia X, Fan S, Dong W, Li S, Zhang Y, Ma Y, Wang S. Jia X, et al. Among authors: ma y. J Biomol Struct Dyn. 2023;41(24):15411-15420. doi: 10.1080/07391102.2023.2204385. Epub 2023 Apr 26. J Biomol Struct Dyn. 2023. PMID: 37126536

4

Design potential selective inhibitors for treating cancer by targeting the Src homology 2 (SH2) domain-containing phosphatase 2 (Shp2) with core hopping approach.

Duan YQ, Ma Y, Wang XJ, Jin YY, Wang RL, Dong WL, Xu WR, Kong DX, Wang SQ. Duan YQ, et al. Among authors: ma y. Protein Pept Lett. 2014 Jun;21(6):556-63. doi: 10.2174/0929866521666131223143913. Protein Pept Lett. 2014. PMID: 24364859

5

The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches.

Li HL, Ma Y, Ma Y, Li Y, Chen XB, Dong WL, Wang RL. Li HL, et al. Among authors: ma y. Oncotarget. 2017 May 16;8(20):33225-33240. doi: 10.18632/oncotarget.16600. Oncotarget. 2017. PMID: 28402259 Free PMC article.

6

Design and synthesis of imidazolidine-2,4-dione derivatives as selective inhibitors by targeting protein tyrosine phosphatase-1B over T-cell protein tyrosine phosphatase.

Ma Y, Sun SX, Cheng XC, Wang SQ, Dong WL, Wang RL, Xu WR. Ma Y, et al. Chem Biol Drug Des. 2013 Nov;82(5):595-602. doi: 10.1111/cbdd.12189. Epub 2013 Aug 21. Chem Biol Drug Des. 2013. PMID: 23848232

7

Computational modeling of mast cell tryptase family informs selective inhibitor development.

Ma Y, Li B, Zhao X, Lu Y, Li X, Zhang J, Wang Y, Zhang J, Wang L, Meng S, Hao J. Ma Y, et al. iScience. 2024 Aug 21;27(9):110739. doi: 10.1016/j.isci.2024.110739. eCollection 2024 Sep 20. iScience. 2024. PMID: 39280611 Free PMC article.

8

Design, synthesis, biological activity and molecular dynamics studies of specific protein tyrosine phosphatase 1B inhibitors over SHP-2.

Sun SX, Li XB, Liu WB, Ma Y, Wang RL, Cheng XC, Wang SQ, Liu W. Sun SX, et al. Among authors: ma y. Int J Mol Sci. 2013 Jun 17;14(6):12661-74. doi: 10.3390/ijms140612661. Int J Mol Sci. 2013. PMID: 23774838 Free PMC article.

9

3D QSAR Pharmacophore Based Virtual Screening for Identification of Potential Inhibitors for CDC25B.

Ma Y, Li HL, Chen XB, Jin WY, Zhou H, Ma Y, Wang RL. Ma Y, et al. Comput Biol Chem. 2018 Apr;73:1-12. doi: 10.1016/j.compbiolchem.2018.01.005. Epub 2018 Jan 31. Comput Biol Chem. 2018. PMID: 29413811

10

Screening and molecular docking verification of feature genes related to phospholipid metabolism in hepatocarcinoma caused by hepatitis B.

Zhang J, Zhang F, Zhang L, Zhang M, Liu S, Ma Y. Zhang J, et al. Among authors: ma y. Lipids Health Dis. 2024 Aug 24;23(1):268. doi: 10.1186/s12944-024-02253-3. Lipids Health Dis. 2024. PMID: 39182089 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42,891 results

Search Page

Filters